Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atipeksen for Ataxia-Telangiectasia
NCT07215416Phase 2Recruiting
- Start
- Aug 2026
- Primary completion
- Dec 2032
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of atipeksen in ataxia-telangiectasia (AT). Started Aug 2026; status: recruiting.
02
Drugs
atipeksen
03
Conditions
ataxia-telangiectasia (AT)
Beyond the preview
Go deeper on NCT07215416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07215416.